We advocate for compounding pharmacies and facilities on a range of state and federal issues affecting patient access to compounded medications. We represent pharmacists and technicians in both traditional 503A compounding pharmacies and 503B outsourcing facilities, as well as prescribers, patients, educators, and suppliers. We’re 5,000 members strong and growing.
Our new “Snapshot of Pharmacy Compounding in America” paints the clearest picture available of the compounding profession today.
Novo Nordisk is still pushing to have semaglutide added to the Demonstrably Difficult to Compound List.
The 11th Circuit Court of Appeals has accepted our amicus brief in Novo Nordisk’s lawsuit against three Florida pharmacies.
A compounding bill in the Indiana senate was improved before it left committee, but it still has a lot of problems.
If you own or manage a pharmacy, you probably want it to stick around — the Owner Summit has sessions to help you do it.
.png?width=410&height=320&name=image-container%20(1).png)
.png?width=410&height=320&name=image-container%20(2).png)
.png?width=411&height=320&name=image-container%20(3).png)
.png?width=410&height=320&name=image-container%20(4).png)
.png)
.png?width=17&height=16&name=folder%20(1).png){kind=small}
%20Pharma-GS.png)